A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: indicative (22), suggestive (83)

Papers Trust Board - 13 January 2026

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 13/01/2026 9:00 - 13:00 Conference Room, Heartbeat Education
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Papers-Trust-Board-13-January-2026.pdf

Dr Schaida Schirwani publications

Description
Dr Schaida Schirwani selected publications 1. Cragg, A., et al., Schirwani, S., et al., Early onset basal cell carcinoma
Url
/Media/UHS-website-2019/Docs/Consultant-publications-lists/Dr-Schaida-Schirwani-publications.pdf

Trastuzumab (21 day-Maintenance)

Description
Chemotherapy Protocol BREAST CANCER TRASTUZUMAB (21 day- Maintenance) Regimen • Breast Cancer – Trastuzumab (21 day-Maintenance)
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Trastuzumab-21-day-Maintenance.pdf

Trastuzumab (21 day-Load)

Description
Chemotherapy Protocol BREAST CANCER TRASTUZUMAB (21 day-Load) Regimen • Breast Cancer – Trastuzumab (21 day-Load) Indicat
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Trastuzumab-21-day-Load.pdf

Trastuzumab Main

Description
Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER TRASTUZUMAB (21 day-Maintenance) Regimen • GI (upper) – Trastuzumab (2
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/TrastuzumabMainVer1.2.pdf

Crizanlizumab Ver 1

Description
Chemotherapy Protocol Recurrent Vaso-Occlusive Crises in Sickle Cell Disease CRIZANLIZUMAB Regimen • Recurrent Vaso-Occlusive Crises in Sickle Cell Diseas
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sickle-Cell/Crizanlizumab-Ver-1.pdf

Papers Trust Board - 29 November 2022

Description
Date Time Location Chair Agenda Trust Board – Open Session 29/11/2022 9:00 - 13:20 Conference Room, Heartbeat/Microsoft Team
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Trust-Board-29-November-2022.pdf

Cytarabine1500

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (1500mg/m2) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cytarabine (15
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine1500.pdf

Gemcitabine

Description
Chemotherapy Protocol PANCREATIC CANCER GEMCITABINE Regimen  Pancreatic Cancer – Gemcitabine Indication  Adj
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Pancreas/Gemcitabine.pdf

Gemcitabine

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEMCITABINE Regimen NSCLC - Gemcitabine Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gemcitabinever12.pdf
141 to 150 of 527
Previous … 13 14 15 16 17 … Next